高效液相色谱-串联质谱法检测中毒患者尿液中的氯巴扎姆及其代谢物
- 作者: Volkova A.A.1,2, Kalekin R.A.1,2, Orlova A.M.1
-
隶属关系:
- Russian Centre of Forensic Medical Expertise
- Peoples› Friendship University of Russia
- 期: 卷 8, 编号 4 (2022)
- 页面: 47-55
- 栏目: ORIGINAL STUDY ARTICLES
- URL: https://journals.rcsi.science/2411-8729/article/view/122468
- DOI: https://doi.org/10.17816/fm705
- ID: 122468
如何引用文章
全文:
详细
论证。确定氯巴扎姆的急性和致死性中毒事实的问题仍然是分析毒理学的一项紧迫任务。药物氯巴占属于苯二氮卓类药物，由于其在过量和滥用的情况下具有高毒性，因此被列入限制流通的精神活性物质清单中。
该研究的目的是提出一种简单、可靠和敏感的技术，通过现代高效液相色谱-串联质谱检测（HPLC-QqQ-MS/MS）鉴定尿液中的氯巴扎姆及其代谢物。
材料与方法。我们描述了一种简单而敏感的HPLC-QqQ-MS/MS方法，用于定性检测尿液中的氯巴扎姆。
结果。根据研究结果，在选定的色谱条件下，氯巴扎姆的保留时间为5.17分钟，而在尿液中发现的其代谢物（去甲氯巴扎姆）则为4.56分钟。氯巴扎姆最强烈的（主）峰是259 m/z，诺拉扎姆是245 m/z。
结论。首次提出了一种经过验证的HPLC-MS/MS方法，用于调查氯巴扎姆中毒的化学毒物学。在一个模型混合物和一个病人服用氯巴扎姆后的尿液的真实生物基质上都得到了验证。这种技术作为一种确认性检查技术，是对法医临床情况的一种补充。
关键词
作者简介
Alla A. Volkova
Russian Centre of Forensic Medical Expertise; Peoples› Friendship University of Russia
Email: himija@rc-sme.ru
ORCID iD: 0000-0002-9882-2330
Cand. Sci. (Pharm.)
俄罗斯联邦, 12/13, Polikarpov Street, Moscow, 125284; MoscowRoman A. Kalekin
Russian Centre of Forensic Medical Expertise; Peoples› Friendship University of Russia
编辑信件的主要联系方式.
Email: himija@rc-sme.ru
ORCID iD: 0000-0002-4989-3511
SPIN 代码: 2473-7421
Dr. Sci. (Pharm.)
俄罗斯联邦, 12/13, Polikarpov Street, Moscow, 125284; MoscowAlevtina M. Orlova
Russian Centre of Forensic Medical Expertise
Email: himija@rc-sme.ru
ORCID iD: 0000-0002-5419-1418
SPIN 代码: 7685-2315
Cand. Sci. (Pharm.)
俄罗斯联邦, 12/13, Polikarpov Street, Moscow, 125284参考
- Volkova AA, Orlova AM, Kalekin RA, Nevmyatova SR. Analysis of the possibility of conducting a forensic chemical study in case of Clobazam poisoning. Forensic Medical examination. 2022;65(1):35–40. (In Russ). doi: 10.17116/sudmed20226501135
- Markin PA, Moskaleva NE, Appolonova SA, et al. Development of a thin-layer chromatography method for simultaneous determination of Clobazam and zaleplon in a mixture. In: Topical issues of forensic medicine and law. Collection of scientific and practical articles. Kazan; 2021. Р. 158–161. (In Russ).
- Orlova AM, Kalekin RA, Volkova AA, et al. Detection of Clobazam in urine by thin-layer chromatography. Bulletin Voronezh State University. 2021;(3):106–113. (In Russ).
- Gauthier AC, Mattson RH. Clobazam: A safe. Efficacious and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015;21(7):543–548. doi: 10.1111/cns.12399
- Arya R, Giridharan N, Anand V, Garg SK. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev. 2018;2018(7):CD009258. doi: 10.1002/14651858.CD009258.pub3
- Tolbert D, Larsen FA. A comprehensive overview of the clinical pharmacokinetics of Clobazam. J Clin Pharmacol. 2019;59(1):7–19. doi: 10.1002/jcph.1313
- Kheireldin R. A case report of Clobazam toxicity related to cannabidiol and Clobazam drug-drug interaction. Translation University Toledo J Med Sci. 2019;(6):35–36. doi: 10.46570/utjms.vol6-2019-339
- Brigo F, Lattanzi S. Anticonvulsant agents: Benzodiazepines (Clobazam. Clonazepam. Diazepam. Lorazepam. Midazolam). In book: Riederer P., Laux G., Nagatsu T., et al., editors. NeuroPsychopharmacotherapy. Springer Nature Switzerland AG; 2020. Р. 1–8. doi: 10.1007/978-3-319-56015-1_440-1
- Kheireldin R. A case report and literature review of Clobazam toxicity related to cbd and Clobazam drug-drug interaction. J Clin Med Res. 2019. doi: 10.37191/Mapsci-2582-4333-1(2)-012
- Aung T. Rare but life-threatening aspiration pneumonia related to initiation of Clobazam therapy. Epilepsy Behavior Rep. 2020;14:100406. doi: 10.1016/j.ebr.2020.100406
- Huddart R, Leeder JS, Altman RB, Klein TE. Pharm GKB summary: Clobazam pathway. Pharmacokinetics. Pharmacogenet Genomics. 2018;28(4):110–115. doi: 10.1097/FPC.0000000000000327
- Hammer H, Ebert B, Jensen HS, Jensen AA. Functional characterization of the 1.5-benzodiazepine Clobazam and its major active metabolite N-desmethylclobazam at human GABAA receptors expressed in xenopus laevis oocytes. PLoS One. 2015;10(3):e0120239. doi: 10.1371/journal.pone.0120239
- Souri E, Farahani AD, Ahmadkhaniha R, Amini M. A stability indicating HPLC method for the determination of Clobazam and its basic degradation product characterization. Daru. 2014;22(1):49. doi: 10.1186/2008-2231-22-49
- Jensen HS, Nichol K, Lee D, Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAA-receptor complexes. PLoS One. 2014;9(2):e88456. doi: 10.1371/journal.pone.0088456
- Bajaja AO, Ly D, Johnson-Davisab KL. Retrospective analysis of metabolite patterns of Clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. J Mass Spectrom Adv Clin Lab. 2022;(24):100–106. doi: 10.1016/j.jmsacl.2022.04.005
- Laloup M, Fernandez MR, De Boeck G, et al. Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of 26 benzodiazepines and metabolites, zolpidem and zopiclone, in blood, urine, and hair. J Anal Toxicol. 2005;29(7):616–626. doi: 10.1093/jat/29.7.616
补充文件
